[go: up one dir, main page]

FI971155L - Menetelmä tamoksifeenin ja tamoksifeenianalogien uterotrofisen vaikutuksen minimoiseksi - Google Patents

Menetelmä tamoksifeenin ja tamoksifeenianalogien uterotrofisen vaikutuksen minimoiseksi Download PDF

Info

Publication number
FI971155L
FI971155L FI971155A FI971155A FI971155L FI 971155 L FI971155 L FI 971155L FI 971155 A FI971155 A FI 971155A FI 971155 A FI971155 A FI 971155A FI 971155 L FI971155 L FI 971155L
Authority
FI
Finland
Prior art keywords
tamoxifen
minimizing
analogues
uterotrophic effect
uterotrophic
Prior art date
Application number
FI971155A
Other languages
English (en)
Swedish (sv)
Other versions
FI971155A0 (fi
FI971155A7 (fi
Inventor
Henry Uhlman Bryant
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI971155A0 publication Critical patent/FI971155A0/fi
Publication of FI971155A7 publication Critical patent/FI971155A7/fi
Publication of FI971155L publication Critical patent/FI971155L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI971155A 1994-09-20 1995-09-18 Menetelmä tamoksifeenin ja tamoksifeenianalogien uterotrofisen vaikutuksen minimoiseksi FI971155L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,904 US5554628A (en) 1994-09-20 1994-09-20 Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs
PCT/US1995/012345 WO1996009051A1 (en) 1994-09-20 1995-09-18 A method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Publications (3)

Publication Number Publication Date
FI971155A0 FI971155A0 (fi) 1997-03-19
FI971155A7 FI971155A7 (fi) 1997-03-19
FI971155L true FI971155L (fi) 1997-03-19

Family

ID=23195869

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971155A FI971155L (fi) 1994-09-20 1995-09-18 Menetelmä tamoksifeenin ja tamoksifeenianalogien uterotrofisen vaikutuksen minimoiseksi

Country Status (16)

Country Link
US (1) US5554628A (fi)
EP (1) EP0702961B1 (fi)
JP (1) JPH10506111A (fi)
KR (1) KR970705999A (fi)
AT (1) ATE220919T1 (fi)
AU (1) AU692932B2 (fi)
CA (1) CA2200205A1 (fi)
CZ (1) CZ82097A3 (fi)
DE (1) DE69527480D1 (fi)
FI (1) FI971155L (fi)
HU (1) HUT77954A (fi)
MX (1) MX9702037A (fi)
NO (1) NO971229L (fi)
NZ (1) NZ294176A (fi)
RU (1) RU2158589C2 (fi)
WO (1) WO1996009051A1 (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
ATE295834T1 (de) * 1997-08-07 2005-06-15 Lilly Co Eli 1-(4-substituierte alkoxy)benzylnaphthalinderivate als östrogeninhibitoren
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
WO2005073206A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
KR101311534B1 (ko) * 2010-12-27 2013-09-25 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
WO2012091425A2 (ko) * 2010-12-27 2012-07-05 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
WO2012119010A2 (en) * 2011-03-01 2012-09-07 Indiana University Research And Technology Corporation Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
WO2013134230A1 (en) * 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
CZ305571B6 (cs) * 2014-01-29 2015-12-16 Smart Brain s.r.o. Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
AU555658B2 (en) * 1981-04-03 1986-10-02 Eli Lilly And Company Benzothiophene compounds
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Also Published As

Publication number Publication date
KR970705999A (ko) 1997-11-03
CZ82097A3 (en) 1997-08-13
EP0702961A2 (en) 1996-03-27
NO971229D0 (no) 1997-03-17
JPH10506111A (ja) 1998-06-16
WO1996009051A1 (en) 1996-03-28
HUT77954A (hu) 1998-12-28
ATE220919T1 (de) 2002-08-15
NO971229L (no) 1997-03-17
EP0702961A3 (en) 1999-11-10
FI971155A0 (fi) 1997-03-19
MX9702037A (es) 1997-06-28
DE69527480D1 (de) 2002-08-29
EP0702961B1 (en) 2002-07-24
AU692932B2 (en) 1998-06-18
CA2200205A1 (en) 1996-03-28
US5554628A (en) 1996-09-10
FI971155A7 (fi) 1997-03-19
RU2158589C2 (ru) 2000-11-10
NZ294176A (en) 1999-10-28
AU3686295A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
FI951184A7 (fi) Taikinaa sisältävä yhdistelmä sekä menetelmä sen valmistamiseksi
NO972911D0 (no) Stabiliserte ribozym-analoger
FI964102L (fi) Menetelmä fenolin ja fenolijohdannaisten valmistamiseksi
DE69534416D1 (de) Verfahren und formulierungen zur bekämpfung von schadinsekten
DE69523060D1 (de) Luziferase-markierungsmethode
FI971202L (fi) Levobupivakaiinin ja sen analogien valmistuksessa käytettäviä menetelmiä rasemisoinnin ja asymmetrisen muuntamisen tekemiseksi
FI971750A7 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
FI971155L (fi) Menetelmä tamoksifeenin ja tamoksifeenianalogien uterotrofisen vaikutuksen minimoiseksi
FI962795L (fi) Menetelmä prosessorin resetoimiseksi ja vahtikoira
FI954798A7 (fi) Tuuletusside
IT1269916B (it) Procedimento migliorato per la sintesi di dimetilcarbonato
BR9505995A (pt) Composto método para tratamentos e composição farmacêutica
FI954408L (fi) Laite ja menetelmä paistamista varten
FI972551L (fi) Päällystyslaite ja menetelmä sitä varten
FI942528L (fi) Kenkä ja menetelmä kengän kiinnittämiseksi
IT1273249B (it) Metodo e macchina per la realizzazione di sigarette ventilate
KR960007598A (ko) 비스락톤계화합물 및 그 제조방법
EE9500004A (et) Meetod bensaldehüüdi valmistamiseks
FI943519L (fi) Menetelmä ja laite rakenteiden valmistamiseksi
FI955110L (fi) Menetelmä massan sakeuden lisäämiseksi
KR960008738U (ko) 온습기
FI971378L (fi) Menetelmiä ja välituotteita 3-aminobentso(b)-atsepinonien valmistusta varten
FI943684A0 (fi) Menetelmä valonhimmentimen toiminnan säätämiseksi ja valonhimmennin
BR9401819A (pt) Método e dispositivos para elaboração de decoração de edificaçães com emprego de plantas